Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
JAG1
REST API REST API
Homo sapiens
JAG1 is differentially expressed in 386 experiments: 180 organism parts: bone marrow, prostate, ... (178 more);, 261 disease states: normal, control, ... (259 more);, 121 cell types 495 cell lines 54 compound treatments and 78 other conditions.
Synonyms CD339, JAGL1, AWS, HJ1, AGS, AHD
Orthologs Jag1 (Mus musculus)   ENSCING00000004617 (Ciona intestinalis)   jag1b (Danio rerio)   Jag1 (Rattus norvegicus)   JAG1 (Bos taurus)   jag1a (Danio rerio)   Q90819_CHICK (Gallus gallus)   Ser (Drosophila melanogaster)   jag1 (Xenopus laevis)   JAG1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, plasma membrane, protein binding, morphogenesis of an epithelial sheet, regulation of cell proliferation, cell fate determination, membrane, positive regulation of Notch signaling pathway, structural molecule activity, growth factor activity, extracellular region, cell communication, Notch receptor processing, hemopoiesis, multicellular organismal development, integral to plasma membrane, regulation of cell migration, Notch binding, nervous system development, Notch signaling pathway, apical part of cell, integral to membrane, negative regulation of cell differentiation, calcium ion binding, organ morphogenesis, inner ear development, positive regulation of myeloid cell differentiation, keratinocyte differentiation, myoblast differentiation, negative regulation of neuron differentiation, response to muramyl dipeptide, endothelial cell differentiation, negative regulation of fat cell differentiation, auditory receptor cell differentiation, distal tubule development, neuronal stem cell maintenance, loop of Henle development, negative regulation of stem cell differentiation
InterPro Term Notch_ligand_N, VWF_C, EGF_extracell, EGF, DSL, VWC_out, EGF_3, EGF-like, EGF-like_Ca-bd
Gene-Disease Assocation TETRALOGY OF FALLOT, JAGGED 1; JAG1, ALAGILLE SYNDROME 1; ALGS1
UniProt Accession B7U6M8, B7U6M9, B5M914, B4DYR1, P78504
Search EB-eye ENSG00000101384
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, ... (50 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MDA-MB-231
3
E-GEOD-5823, E-MTAB-62, E-TABM-420
AGS
2
E-GEOD-15460, E-MTAB-37
K562
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
489 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (61 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-MTAB-25, E-GEOD-19069, E-AFMX-5, E-GEOD-6740
mononuclear cell
2
E-GEOD-7307, E-GEOD-6053
macrophage
1
2
E-GEOD-3982, E-GEOD-360, E-GEOD-8286
adult choroid from 76 y.o. donor
1
E-GEOD-18811
CD16+ dendritic cell
1
E-TABM-34
multipotent adult progenitor cell
1
E-MEXP-466
115 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (70 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
glioblastoma
1
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-4412
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MEXP-1331, E-MTAB-62
255 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-2639, E-GEOD-5741, E-TABM-782, E-GEOD-3720, ... (40 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
hydroxyurea
1
E-GEOD-6431
MIG control
1
E-GEOD-15811
indomethacin
1
E-MEXP-1337
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
ponasterone A
1
E-GEOD-3113
48 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86
1
1
E-GEOD-3494
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, ... (9 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-2666, E-MEXP-2283, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-TABM-577, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6207, E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-4025, ... (11 experiments)

Genotype
studied in E-MEXP-1437, E-TABM-1029, E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-21612, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (40 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, ... (10 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (11 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Processing time: 0.317 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM